Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo.
Overview
- Experimental NeuroImmunology, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD UK
- Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD UK
- Parkinson’s UK, London, UK
- Present Address: Curve Therapeutics, Southampton Science Park, Southampton, SO16 7NS UK
- Institute for Life Sciences, University of Southampton, Highfield, Southampton, UK
- BioInvent International AB, Solvegatan 41, 22370 Lund, Sweden
Abstract
Parkinson’s disease (PD), the most prevalent neurodegenerative movement disorder, is characterised by widespread alpha-synuclein (α-Syn) pathology in the brain and the progressive degeneration of nigrostriatal dopaminergic neurons. Experimental and clinicopathological data support a templated, prion-like component to α-Syn spread; however, the cellular mechanisms governing fibril uptake and intercellular transmission remain incompletely defined. Fc gamma receptor IIb (FcγRIIb or CD32b), the sole cross-species inhibitory Fcγ receptor, has been implicated in α-Syn internalisation in vitro, though its contribution to α-Syn propagation in vivo is not well established. Here, we examine the role of FcγRIIb in α-Syn seeding, propagation, and neurotoxicity in vivo using the preformed fibril (PFF) α-Syn intracranial injection model in mice. Genetic ablation of murine FcγRII reduced phosphorylated α-Syn (pα-Syn) burden and anatomical distribution across multiple brain regions at 90 days post-PFF injection, consistent with impaired development of Lewy-like pathology. Attenuated pα-Syn pathology was accompanied by reduced microglial reactivity, preservation of nigrostriatal dopaminergic integrity, and protection from PFF-associated motor and exploratory deficits. In parallel, pharmacological blockade of human (h) FcγRIIb using monoclonal antibodies reduced acute-phase pα-Syn accumulation in hFcγRIIb-transgenic mice following PFF challenge. Collectively, these findings identify FcγRIIb as a critical regulator of α-Syn propagation in vivo and support receptor-targeted blockade as a mechanistically distinct and therapeutically tractable strategy for modifying disease progression in PD and related α-synucleinopathies.
Supplementary Information: The online version contains supplementary material available at https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- uniprot.org/
align , at UniProt; found in the text, “Discussion”
Data availability
The data supporting the findings of this study are available from the corresponding author upon request. All data were generated and analysed during the current study. A version of this manuscript (preprint) is available in the public domain in the BioRxiv (BioArchive) repository (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Publisher: n/a → Springer Science+Business Media
- Funding: added Gerald Kerkut Charitable Trust; University of Southampton; Wessex Medical Research
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 11 authors, 6 keywords, 14 MeSH terms, 42 references.
Cite
This paper
Hennegan, J. M., Hurley, M. J., Colley, M., Cox, K. L., Douglas, L. R., Duriez, P. J., Oldham, R. J., Cragg, M. S., Frendéus, B., Roghanian, A., & Teeling, J. L. (2026). Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta neuropathologica, 152(1), 40. https://
BibTeX
@article{hennegan2026del
author = {Hennegan, James M and Hurley, Michael J and Colley, Matthew and Cox, Kerry L and Douglas, Leon R and Duriez, Patrick J and Oldham, Robert J and Cragg, Mark S and Frendéus, Björn and Roghanian, Ali and Teeling, Jessica L},
title = {{Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo}},
journal = {Acta neuropathologica},
year = {2026},
month = sep,
volume = {152},
number = {1},
pages = {40},
publisher = {Springer Science+Business Media},
issn = {0001-6322},
doi = {10.1007/
url = {https://
pmid = {42789107},
pmcid = {PMC13615098}
}
RIS
TY - JOUR
AU - Hennegan, James M
AU - Hurley, Michael J
AU - Colley, Matthew
AU - Cox, Kerry L
AU - Douglas, Leon R
AU - Duriez, Patrick J
AU - Oldham, Robert J
AU - Cragg, Mark S
AU - Frendéus, Björn
AU - Roghanian, Ali
AU - Teeling, Jessica L
TI - Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo
T2 - Acta neuropathologica
J2 - Acta Neuropathol
PY - 2026
DA - 2026/
VL - 152
IS - 1
SP - 40
SN - 0001-6322
PB - Springer Science+Business Media
DO - 10.1007/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1007/
"type": "article-journal",
"title": "Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo",
"container-title": "Acta neuropathologica",
"author": [
{
"family": "Hennegan",
"given": "James M"
},
{
"family": "Hurley",
"given": "Michael J"
},
{
"family": "Colley",
"given": "Matthew"
},
{
"family": "Cox",
"given": "Kerry L"
},
{
"family": "Douglas",
"given": "Leon R"
},
{
"family": "Duriez",
"given": "Patrick J"
},
{
"family": "Oldham",
"given": "Robert J"
},
{
"family": "Cragg",
"given": "Mark S"
},
{
"family": "Frendéus",
"given": "Björn"
},
{
"family": "Roghanian",
"given": "Ali"
},
{
"family": "Teeling",
"given": "Jessica L"
}
],
"container-title-short":
"volume": "152",
"issue": "1",
"page": "40",
"DOI": "10.1007/
"PMID": "42789107",
"PMCID": "PMC13615098",
"ISSN": "0001-6322",
"publisher": "Springer Science+Business Media",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
9,
25
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1038/s41467-024-49016-3
- Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein.Journal: Nature communicationsIn common: Parkinson's, mouse, cellular / molecular, 6 references
- [2] doi:10.1016/j.isci.2025.111935
- SENP2-based N-terminal truncation of α-synuclein in Lewy pathology propagation.Journal: iScienceIn common: Parkinson's, cellular / molecular, 6 references
- [3] doi:10.1371/journal.ppat.1010018
- Interaction between coxsackievirus B3 infection and α-synuclein in models of Parkinson's disease.Journal: PLoS pathogensIn common: Parkinson's, mouse, cellular / molecular, 4 references
- [4] doi:10.1126/sciadv.adq3539
- Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases.Journal: Science advancesIn common: Parkinson's, mouse, cellular / molecular, 4 references
- [5] doi:10.1038/s41531-023-00620-y
- Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils.Journal: NPJ Parkinson's diseaseIn common: Parkinson's, cellular / molecular, 4 references
- [6] doi:10.1038/s41419-024-06534-8
- Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.Journal: Cell death & diseaseIn common: Parkinson's, mouse, cellular / molecular, 4 references
- [7] doi:10.1038/s41467-026-68870-x
- Anti-TLR2 immunotherapy modulates neuron-to-oligodendrocyt
e propagation of α-synuclein in mouse and human models. Journal: Nature communicationsIn common: Parkinson's, mouse, cellular / molecular, 3 references - [8] doi:10.1186/s40035-026-00535-7
- Mapping cellular vulnerability in Parkinson's disease using retro-AAVs and preformed α-synuclein fibrils.Journal: Translational neurodegenerationIn common: Parkinson's, mouse, cellular / molecular, 4 references
- [9] doi:10.1186/s13024-024-00756-2
- α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease.Journal: Molecular neurodegenerationIn common: Parkinson's, mouse, cellular / molecular, 4 references
- [10] doi:10.1038/s41531-025-01055-3
- Parkinson's paradox: alpha-synuclein's selective strike on SNc dopamine neurons over VTA.Journal: NPJ Parkinson's diseaseIn common: Parkinson's, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
